These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 27597408

  • 1. Design, synthesis, biological evaluation and molecular docking study on peptidomimetic analogues of XK469.
    Xia QH, Hu W, Li C, Wu JF, Yang L, Han XM, Shen YM, Li ZY, Li X.
    Eur J Med Chem; 2016 Nov 29; 124():311-325. PubMed ID: 27597408
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Design, synthesis, molecular modeling and anti-proliferative evaluation of novel quinoxaline derivatives as potential DNA intercalators and topoisomerase II inhibitors.
    Ibrahim MK, Taghour MS, Metwaly AM, Belal A, Mehany ABM, Elhendawy MA, Radwan MM, Yassin AM, El-Deeb NM, Hafez EE, ElSohly MA, Eissa IH.
    Eur J Med Chem; 2018 Jul 15; 155():117-134. PubMed ID: 29885574
    [Abstract] [Full Text] [Related]

  • 4. Design, efficient synthesis, docking studies, and anticancer evaluation of new quinoxalines as potential intercalative Topo II inhibitors and apoptosis inducers.
    Abbass EM, Khalil AK, Mohamed MM, Eissa IH, El-Naggar AM.
    Bioorg Chem; 2020 Nov 15; 104():104255. PubMed ID: 32927130
    [Abstract] [Full Text] [Related]

  • 5. Discovery and antiproliferative evaluation of new quinoxalines as potential DNA intercalators and topoisomerase II inhibitors.
    Eissa IH, Metwaly AM, Belal A, Mehany ABM, Ayyad RR, El-Adl K, Mahdy HA, Taghour MS, El-Gamal KMA, El-Sawah ME, Elmetwally SA, Elhendawy MA, Radwan MM, ElSohly MA.
    Arch Pharm (Weinheim); 2019 Nov 15; 352(11):e1900123. PubMed ID: 31463953
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Identification of 3-(benzazol-2-yl)quinoxaline derivatives as potent anticancer compounds: Privileged structure-based design, synthesis, and bioactive evaluation in vitro and in vivo.
    Liu QQ, Lu K, Zhu HM, Kong SL, Yuan JM, Zhang GH, Chen NY, Gu CX, Pan CX, Mo DL, Su GF.
    Eur J Med Chem; 2019 Mar 01; 165():293-308. PubMed ID: 30685528
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.
    My Van HT, Woo H, Jeong HM, Khadka DB, Yang SH, Zhao C, Jin Y, Lee ES, Youl Lee K, Kwon Y, Cho WJ.
    Eur J Med Chem; 2014 Jul 23; 82():181-94. PubMed ID: 24904965
    [Abstract] [Full Text] [Related]

  • 11. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P, Woo H, Jun KY, Kadi AA, Abdel-Aziz HA, Kwon Y, Rahman AF.
    Bioorg Med Chem; 2016 Apr 15; 24(8):1898-908. PubMed ID: 26988802
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety.
    Thapa P, Karki R, Yun M, Kadayat TM, Lee E, Kwon HB, Na Y, Cho WJ, Kim ND, Jeong BS, Kwon Y, Lee ES.
    Eur J Med Chem; 2012 Jun 15; 52():123-36. PubMed ID: 22503656
    [Abstract] [Full Text] [Related]

  • 13. Synthesis and biological evaluation of amino-substituted benzo[f]pyrido[4,3-b] and pyrido[3,4-b]quinoxalines: a new class of antineoplastic agents.
    Nguyen CH, Fan E, Riou JF, Bissery MC, Vrignaud P, Lavelle F, Bisagni E.
    Anticancer Drug Des; 1995 Jun 15; 10(4):277-97. PubMed ID: 7786395
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and antitumor properties of N-[2-(dimethylamino)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: a new class of putative topoisomerase inhibitors.
    Deady LW, Kaye AJ, Finlay GJ, Baguley BC, Denny WA.
    J Med Chem; 1997 Jun 20; 40(13):2040-6. PubMed ID: 9207945
    [Abstract] [Full Text] [Related]

  • 15. Design, synthesis and biological evaluation of (E)-2-(2-arylhydrazinyl)quinoxalines, a promising and potent new class of anticancer agents.
    Rodrigues FA, Bomfim Ida S, Cavalcanti BC, Pessoa Cdo Ó, Wardell JL, Wardell SM, Pinheiro AC, Kaiser CR, Nogueira TC, Low JN, Gomes LR, de Souza MV.
    Bioorg Med Chem Lett; 2014 Feb 01; 24(3):934-9. PubMed ID: 24398294
    [Abstract] [Full Text] [Related]

  • 16. XK469, a selective topoisomerase IIbeta poison.
    Gao H, Huang KC, Yamasaki EF, Chan KK, Chohan L, Snapka RM.
    Proc Natl Acad Sci U S A; 1999 Oct 12; 96(21):12168-73. PubMed ID: 10518594
    [Abstract] [Full Text] [Related]

  • 17. Part I: Synthesis, cancer chemopreventive activity and molecular docking study of novel quinoxaline derivatives.
    Galal SA, Abdelsamie AS, Tokuda H, Suzuki N, Lida A, Elhefnawi MM, Ramadan RA, Atta MH, El Diwani HI.
    Eur J Med Chem; 2011 Jan 12; 46(1):327-40. PubMed ID: 21145626
    [Abstract] [Full Text] [Related]

  • 18. Molecular modeling studies and synthesis of novel quinoxaline derivatives with potential anticancer activity as inhibitors of c-Met kinase.
    Abbas HA, Al-Marhabi AR, Eissa SI, Ammar YA.
    Bioorg Med Chem; 2015 Oct 15; 23(20):6560-72. PubMed ID: 26420384
    [Abstract] [Full Text] [Related]

  • 19. Synthesis and antitumor activities of a series of novel quinoxalinhydrazides.
    Grande F, Aiello F, Grazia OD, Brizzi A, Garofalo A, Neamati N.
    Bioorg Med Chem; 2007 Jan 01; 15(1):288-94. PubMed ID: 17085054
    [Abstract] [Full Text] [Related]

  • 20. DNA sequence specificity for topoisomerase II poisoning by the quinoxaline anticancer drugs XK469 and CQS.
    Gao H, Yamasaki EF, Chan KK, Shen LL, Snapka RM.
    Mol Pharmacol; 2003 Jun 01; 63(6):1382-8. PubMed ID: 12761349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.